Imran Farooq, MD
Interventional Cardiology · Orlando, FLNPI 1093942393
Payments from drug & device makers
Across 143 payments — averaging $47.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Philips North America LLC$991
- Kestra Medical Technology Services, Inc.$575
- Medtronic$532
- Penumbra, Inc.$528
- Silk Road Medical, Inc.$522
- plus $3K from 21 others
What the payments were for
- Travel & lodging$1,21818%
- Food & beverage$5,64282%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 16 | $1,134 |
| Philips North America LLC | 5 | $991 |
| Kestra Medical Technology Services, Inc. | 14 | $575 |
| Medtronic(2 entities) | 17 | $532 |
| Penumbra, Inc. | 13 | $528 |
| Silk Road Medical, Inc. | 4 | $522 |
| Abiomed | 13 | $480 |
| Inari Medical, Inc. | 3 | $438 |
| Shockwave Medical, Inc | 2 | $274 |
| Cook Medical LLC | 6 | $190 |
| Boston Scientific | 4 | $185 |
| Endologix LLC | 2 | $132 |
| Novartis | 8 | $129 |
| Cordis US CORP. | 3 | $113 |
| Amgen | 6 | $110 |
| Johnson & Johnson | 1 | $98 |
| Livanova USA, Inc. | 2 | $92 |
| Cardiovascular Systems Inc. | 5 | $87 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $62 |
| Merck | 2 | $38 |
| Alnylam Pharmaceuticals Inc. | 1 | $29 |
| AstraZeneca | 2 | $28 |
| Heartflow, Inc. | 1 | $23 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Bard Peripheral Vascular, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $17 |
| Cardiva Medical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IGT D Peripheral$916
- FLOWTRIEVER CATHETER, S$613
- ENROUTE .014 Guidewire$464
- ENROUTE Transcarotid Stent$464
- ENROUTE Transcarotid Neuroprotection System$464
- ENHANCE Transcarotid Peripheral Access Kit$464
- Omnilink Elite vascular stent system$457
- Indigo System$372
- Assure WCD$370
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$274
- AMPLATZER Occluders$184
- CT THROMBECTOMY SYSTEM KIT$176
- GENERAL VASCULAR INTERVENTION$139
- Trifecta GT Tissue Heart Valve$113
- IN.PACT Admiral$113
How this compares
$6,860 in reported general payments places this provider in the 40th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 305 | $336,705 |
| Repatha SureclickEvolocumab | 64 | $81,116 |
| XareltoRivaroxaban | 49 | $43,920 |
| EntrestoSacubitril/Valsartan | 32 | $37,359 |
| JardianceEmpagliflozin | 24 | $31,667 |
| BrilintaTicagrelor | 16 | $20,459 |
| Repatha SyringeEvolocumab | 11 | $10,939 |
| LivaloPitavastatin Calcium | 12 | $7,724 |
| Metoprolol Succinate | 338 | $4,652 |
| Ranolazine ErRanolazine | 25 | $4,338 |
| Atorvastatin Calcium | 403 | $3,876 |
| ClopidogrelClopidogrel Bisulfate | 331 | $3,134 |
| Ezetimibe | 165 | $2,895 |
| Rosuvastatin Calcium | 206 | $2,346 |
| Losartan Potassium | 178 | $1,625 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $98 | $43,92049 claims |
| NovartisEntresto | $129 | $37,35932 claims |
| AstraZenecaBrilinta | $28 | $20,45916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Orlando
- Vijaykumar KasiOrlando$1.1M
- Zahid AminOrlando$670K
- Farhan KhawajaOrlando$636K
- Dominick AngiolilloJacksonville$4M
- Douglas SpriggsClearwater$3.2M
- Rakesh PrashadOcala$3.1M
- Aldo Martinez FleitesMiami Lakes$2.2M
- Rohit AminPensacola$2M
- Roberto CubedduNaples$2M
- Arthur LeeGainesville$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.